Interim recommendations of the advisory committee on immunization practices for use of Moderna and Pfizer-Biontech Covid-19 vaccines in children aged 6 months5 years: United States, june 2022
MMWR recomm. rep
; 71(26): 859-868, July 1, 2022.
Artigo
em Inglês
| BIGG - guias GRADE
| ID: biblio-1397012
Biblioteca responsável:
BR1.1
ABSTRACT
On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine for use in children aged 6 months4 years, administered as 3 doses (3 µg [0.2 mL] each), at intervals of 3 weeks between doses 1 and 2 and ≥8 weeks between doses 2 and 3. On June 18, 2022, the Advisory Committee on Immunization Practices (ACIP) issued separate interim recommendations for use of the Moderna COVID-19 vaccine in children aged 6 months5 years and the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months4 years for the prevention of COVID-19.* Both the Moderna and Pfizer-BioNTech COVID-19 vaccines met the criteria for immunobridging, which is the comparison of neutralizing antibody levels postvaccination in young children with those in young adults in whom efficacy had been demonstrated. Descriptive efficacy analyses were also conducted for both Moderna and Pfizer-BioNTech COVID-19 vaccines during the period when the Omicron variant of SARS-CoV-2 (the virus that causes COVID-19) predominated. No specific safety concerns were identified among recipients of either vaccine. ACIP recommendations for the use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months5 years and 6 months4 years, respectively, are interim and will be updated as additional information becomes available. Vaccination is important for protecting children aged 6 months5 years against COVID-19.
Texto completo:
Disponível
Coleções:
Bases de dados temática
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Problema de saúde:
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Pneumonía
Base de dados:
BIGG - guias GRADE
Assunto principal:
COVID-19
/
Vacina BNT162
/
Vacina de mRNA-1273 contra 2019-nCoV
Tipo de estudo:
Guia de prática clínica
/
Estudo prognóstico
Idioma:
Inglês
Revista:
MMWR recomm. rep
Ano de publicação:
2022
Tipo de documento:
Artigo